SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director & President: Yoshitaka Kitao; hereinafter “SBIP”), a subsidiary company of SBI Holdings, Inc. which conducts research and development pharmaceuticals, etc., utilizing 5-aminolevulinic acid (*) announces today that the medical light source device “Aladuck405/II” (hereafter “Aladuck”) marketed in Japan has been registered as a class II medical device with the U.S. FDA (Food and Drug Administration).